Merck Stock Upgraded Amid Acquisition Talks
Wolfe Research upgraded Merck to Outperform with a $135 target on January 8. On January 9, reports emerged of Merck in talks to acquire Revolution Medicines for around $30 billion.
Topic
Latest reporting and analysis tagged with oncology.
Wolfe Research upgraded Merck to Outperform with a $135 target on January 8. On January 9, reports emerged of Merck in talks to acquire Revolution Medicines for around $30 billion.
Stifel and Mizuho increased price targets for Guardant Health on January 9, citing anticipated growth in 2026. The company is a precision oncology firm known for liquid biopsy tests.
Illumina launched a cloud-based multiomics platform on January 6. On January 7, TD Cowen raised its price target for the company while maintaining a Hold rating.
Exelixis faces mixed analyst reactions after a strategic collaboration and preliminary 2025 revenue report, with price targets adjusted and focus on zanzalintinib's 2026 launch.
Novartis AG opened a radioligand therapy facility in Florida on January 9, part of a $23 billion U.S. investment. On January 6, Barclays upgraded the stock to Equal Weight with a CHF 120 target.
Genmab A/S partners with Anthropic to enhance R&D using AI, following a Deutsche Bank price target increase for the oncology-focused biotech firm.